These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 7542184)
41. L-tryptophan and eosinophilia-myalgia syndrome. Shapiro S Lancet; 1994 Apr; 343(8904):1035-7. PubMed ID: 7909063 [No Abstract] [Full Text] [Related]
42. Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report. Smith E; Gordon M; Lebwohl M Cutis; 2006 Jun; 77(6):361-4. PubMed ID: 16838769 [TBL] [Abstract][Full Text] [Related]
44. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome? Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924 [TBL] [Abstract][Full Text] [Related]
45. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome. Naylor S; Williamson BL; Johnson KL; Gleich GJ Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088 [TBL] [Abstract][Full Text] [Related]
47. Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Keating JP; Wardill K; Viggiano J N Z Med J; 1992 Aug; 105(939):317. PubMed ID: 1386918 [No Abstract] [Full Text] [Related]
48. L-tryptophan and eosinophilia-myalgia syndrome. Mitchell N Med J Aust; 1993 Mar; 158(5):363-4. PubMed ID: 8329035 [No Abstract] [Full Text] [Related]
49. AHR activation by tryptophan--pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome? Rieber N; Belohradsky BH Immunol Lett; 2010 Feb; 128(2):154-5. PubMed ID: 19941898 [TBL] [Abstract][Full Text] [Related]
50. Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use. Varga J; Griffin R; Newman JH; Jimenez SA J Rheumatol; 1991 Feb; 18(2):259-63. PubMed ID: 2023221 [TBL] [Abstract][Full Text] [Related]
51. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395 [No Abstract] [Full Text] [Related]
53. The eosinophilia-myalgia syndrome and tryptophan. Belongia EA; Mayeno AN; Osterholm MT Annu Rev Nutr; 1992; 12():235-56. PubMed ID: 1503805 [No Abstract] [Full Text] [Related]
54. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina. Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177 [TBL] [Abstract][Full Text] [Related]
55. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome. Silver RM; Sutherland SE; Carreira P; Heyes MP J Rheumatol; 1992 Jan; 19(1):69-73. PubMed ID: 1532618 [TBL] [Abstract][Full Text] [Related]